Biotech

While building a bioreactor for NASA, co-founders Jordana Blackman and Tiffanwy Klippel-Cooper imagined a new way to think about how biology and physics intertwine.

We have world-class research and clinical trial strength, but risk aversion and limited capital are holding us back in biotech. Unlocking our potential requires bold investment.

The Sydney startup has built a slow-release capsule that can reach the 70% of livestock methane emissions from cow flatulence and belching ‒ where most other solutions can't go.

Backed by Blackbird, Sydney’s Vexev has clinically proven a world-first autonomous ultrasound robot, performing specialist scans at the press of a button.

CSL’s AGM turned fiery as shareholders raged over pay and profits, as plunging vaccination rates batter the biotech’s bottom line.

Healthcare stocks may be at a turning point after a year of heavy losses and policy turmoil.

ASX biotech stocks rebounded en masse on Monday but there are still concerns Donald Trump's pharma tariffs will cast a shadow over the sector.

Whether or not they ultimately land as promised, the tariffs are a reminder of how economic power is shifting. Australia must build real capability in response.